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Abstract
Background: Preserved residual kidney function (RKF) and normal fluid status are associated with better patient
outcomes in incident haemodialysis patients. The objective of this trial is to determine whether using bioimpedance
technology in prescribing the optimal post-dialysis weight can reduce the rate of decline of RKF and potentially
improve patient outcomes.
Methods/Design: 516 pateints commencing haemodialysis, aged >18 with RKF of > 3 ml/min/1.73 m2 or a urine
volume >500 ml per day or per the shorter inter-dialytic period will be consented and enrolled into a pragmatic, open-
label, randomized controlled trial. The intervention is incorporation of bioimpedance spectroscopy (BI) determination of
normally hydrated weight to set a post-dialysis target weight that limits volume depletion, compared to current
standard practice. Clinicians and participants will be blinded to BI measures in the control group and a standardized
record capturing management of fluid status will be used in all participants. Primary outcome is preservation of
residual kidney function assessed as time to anuria (≤100 ml/day or ≤200 ml urine volume in the short inter-dialytic
period). A sample size of 516 was based upon a cumulative incidence of 30% anuria in the control group and 20% in
the treatment group and 11% competing risks (death, transplantation) over 10 months, with up to 2 years follow-up.
Secondary outcomes include rate of decline in small solute clearance, significant adverse events, hospitalization, loss of
vascular access, cardiovascular events and interventions, dialysis efficacy and safety, dialysis-related symptoms and
quality of life. Economic evaluation will be carried out to determine the cost-effectiveness of the intervention. Analyses
will be adjusted for patient characteristics and dialysis unit practice patterns relevant to fluid management.
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Discussion: This trial will establish the added value of undertaking BI measures to support clinical management of fluid
status and establish the relationship between fluid status and preservation of residual kidney function in incident
haemodialysis patients.
Trial registration: ISCCTN Number: 11342007, completed 26/04/2016; NIHR Portfolio number: CPMS31766; Sponsor:
Keele University
Keywords: Fluid status, Body compostion, Residual kidney function, Haemodialysis, Bioimpedance, Fluid management,
Health economics
Background
Preservation of residual kidney function (RKF) and achiev-
ing normal volume status are recognized as two linked
and critically important predictors of survival in haemodi-
alysis patients. The CANUSA study found that each
250 ml of urine per day increased 2-year survival by 36%
in peritoneal dialysis patients [1] and in the NECOSAD
study complete anuria in haemodialysis (HD) patients in-
creased the relative risk of death 17-fold compared to
those with well-preserved kidney function [2]. A more re-
cent US study found a graded association, with the fastest
rates of RKF loss being associated with doubling of all-
cause mortality [3]. Other reported benefits of RKF in-
clude improved wellbeing, better quality of life [4] and less
need to remove high fluid volumes during dialysis sessions
with reduced risks of intra-dialytic hypotension [5],
cardiac stunning [6] and associated mortality risk [7, 8].
This link between RKF, volume management and out-
comes is further supported by observational studies indi-
cating that increased risks associated with failing to
achieve target weight are bidirectional, implying that both
over- and under-hydration are a threat to patients [9].
Given the value of RKF, it is surprising how few clinical
trials have focussed on interventions to maintain it as a
key benefit to HD patients – the exception being ultrapure
water [10], which is now standard care. Worse than this, a
frequently applied fluid management strategy is to reduce
the post-dialysis target weight until minimal or no anti-
hypertensive drugs are required as evidence of adequate
control of volume status. Our recent survey of fluid man-
agement practice patterns in UK units indicates that this
is still being pursued in the majority of units [11], despite
the risk it poses to residual kidney function by setting in
place a continuing vicious cycle of volume depletion, ex-
cessive thirst and high inter-dialytic fluid gains.
The introduction of bioimpedance (BI) technology,
such as BI spectroscopy, provides clinicians with the op-
portunity to break this cycle while avoiding the risk of
excessive overhydration. BI gives additional information
about body composition available at the bedside [12].
The principle is simple and involves the passing of a
low-strength alternating current through the subject’s
body to measure the resistance and reactance to flow.
These two measures are dependent on the amount of
fluid and cell membranes between the electrodes (usu-
ally placed on the hand and foot on one side of the
body). The measurements are then modelled using infor-
mation such as the subject’s weight and height to esti-
mate the total volume of fluid in the body and the
proportion of this that is within cells or in the extracel-
lular space. In dialysis patients, compared to healthy
subjects, the total amount of fluid (intra plus extracellu-
lar) can be high or low, but often the latter because of
muscle wasting, inflammation or even over-aggressive
fluid removal on dialysis. However, if the extracellular
fluid is disproportionately high, this is a strong signal for
an increased mortality risk [13–15]. For this reason,
until now trials conducted to establish the clinical value
of BI in setting target weights have focussed on clinical
endpoints associated with hypervolaemia, such as high
blood pressure, left ventricular mass and pulse- wave
pressure or worsening extracellular to intracellular fluid
distribution. The results of these interventions have been
mixed, and more trials are clearly needed, but the price
for achieving lower blood pressure through post-dialytic
hypovolaemia was accelerated loss of RKF in one such
study [16]. There is also evidence that presence of RKF
leads to more stable fluid status without intervention in
peritoneal dialysis patients [17]. Thus, BISTRO will es-
tablish the potential for BI to add value to fluid manage-
ment and address the concern that this technology may
be being adopted indiscriminately without clear evidence
of benefit and a potential risk of harm.
Methods/Design
Aim
To determine if incorporation of bioimpedance spectroscopy-
derived information on body composition into the setting of
the post-dialytic target weight reduces loss of re-
sidual kidney function in incident centre-based HD
patients, with the potential to improve clinical out-
comes, dialysis-related symptoms, hospitalization and
survival.
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Trial design
A pragmatic, multicentre, open-label prospective ran-
domized controlled trial comparing current best practice
in setting the post-dialytic target weight (control group)
with the same assessment guided by serial BI measure-
ments (intervention group). BI readings will be taken in
both study groups but the results concealed from the
clinical teams and trial participants in the control limb.
To minimize performance and information bias, the BI
measurements will be taken independently from the
fluid assessments by trained nurses but within the previ-
ous week (i.e. the last 3 dialysis sessions), usually before
sessions.
Study setting
The study will take place in adult, out-patient haemo-
dialysis centres, both main and satellite units, and
their associated inpatient renal units during hospital
admissions. Patients admitted for inter-current prob-
lems while participating in the trial will remain in the
study and be assessed according to randomization.
Participating sites will be available on the dedicated
trial website, www.keele.ac.uk/bistro.
Eligibility criteria
Inclusion criteria
 Adults aged >18 years within 3 months of
commencing centre-based maintenance haemodialysis
due to advanced kidney disease CKD stage 5, planned
or unplanned, via arteriovenous fistula, graft or central
venous catheter (i.e. with or without permanent
vascular access)
 Commencing dialysis on any regimen, including
having incremental dialysis initiation
 Residual kidney function: Patients who have not
yet started, but are about to start, dialysis
treatment should have a daily urine volume >
500 ml/day or a measured mean urea and
creatinine clearance ≥3 ml/min/1.72 m2
determined from a 24-h collection. Patients already on
dialysis should have a urine volume >500 ml during the
short inter-dialytic period or a measured mean
urea and creatinine clearance ≥3 ml/min/1.72 m2,
determined from the same timed inter-dialytic urine
collections and an average of the post and pre dialysis
plasma urea and creatinine concentrations.
Exclusion criteria
 Unable or unwilling to give informed consent
 Unable to comply with trial procedures, e.g.
collection of urine output
 Likely survival prognosis or planned modality
transfer < 6 months
 Subjects with limb amputations when the foot is not
accessible and it is not possible to take hand to hand
measurements
Intervention
The study intervention is the incorporation of bioimpe-
dance technology-derived information about body compos-
ition into the clinical assessment of fluid status of dialysis
patients. The study intervention is the use of this additional
information, specifically the normally hydrated weight, in
conjunction with usual clinical judgement to set a target
dry weight that is as close to normal at the end of a dialysis
session, thus avoiding the risks of over- or under-hydration.
BISTRO is investigator-led with no input into the
study design from industry. Based upon clearly defined
criteria articulated in the original grant application, 6 de-
vice manufacturers were invited to submit proposals to a
panel comprising experts, patient and lay representation
and independent clinician and National Health Service
experts. The Fresenius Body Composition Monitor
(Fresenius BCM) was the device selected based on best
validated device in the renal population both against
gold standard methods (i.e. DEXA scanning, deuterium
and sodium bromide solution) [18] and in referencing
body composition of the dialysis patients to population
norms [15, 19]. The BCM was originally CE-marked to
Fresenius Medical Care as a Class IIa medical device in
2003; the CE mark was last updated in June 2011 [20].
All participating centres will receive bespoke training
at the site visits prior to enrolling patients, which will
include interpretation of BI data for use by fluid
management assessors and a standardized approach to
taking BI measurements by the research nurses. The
study team will provide support for data interpretation
throughout the study (see responsibilities).
Outcomes
Primary Outcome: Preservation of Residual Kidney
Function
 Time to anuria, defined as urine volume ≤100 ml/
day or ≤200 ml in the short inter-dialytic period
confirmed by a further collection after 2 weeks to
exclude temporary illness.
Secondary Outcomes
 The rate of decline in kidney function, defined as
the slope in decline of the average residual urea and
creatinine clearance.
 Significant events, including vascular access failure
and associated interventions, cardiovascular events,
hospital admissions and death, including long-term
legacy effects beyond trial completion using data
linkage.
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 Objective measures of dialysis efficacy and safety:
e.g. inter-dialytic fluid gains, intra-dialytic
hypotension, urea-reduction ratios (routine data)
 Patient-reported outcomes, including quality of life:
EQ-5D-5 L; [21] SF12 [22], dialysis-related symptoms
(Integrated Palliative Care Outcome Scale- Renal,
IPOS) www.pos-pal.org, Patient Activation Measure
[23], Duke Activity Status index [24], Montreal
Cognitive Assessment (MoCA) [25], Client Service
Receipt Inventory (CSRI) for Chronic Disease.
 Cost-effectiveness of the intervention, expressed as
incremental cost per additional quality-adjusted life
year (QALY) gained.
Participant timeline
Trial entry for all participants is at the point of com-
mencing centre-based haemodialysis as an outpatient,
see Fig. 1. At this point trial eligibility will be con-
firmed, followed by randomization. All participants will
be followed up until study completion or withdrawal
because of death, transplantation, stopping dialysis (e.g.
recovery of function) or patient choice, including any
period after they reach the primary outcome so that the
health economic analysis can be completed. The sched-
ule of trial assessments is shown in Table 1.
Sample size
Primary outcome (time to anuria)
It can be determined from cohort studies and data
collection from a large dialysis unit of 615 patients that
the proportion of incident centre-based HD patients
anuric by 10 months is in the region of 30% (range 25–
67%) [26–30]. Sample size is based on a cumulative 10-
month incidence of anuria of 30% in the control group
and 20% in the treatment group and 11% competing
risks (based on death and transplantation data extrapo-
lated from the 2013 UKRR report [31]). Assuming expo-
nential decline, proportional hazards, 90% power and 5%
two-tailed significance, 185 events are required to detect
the corresponding hazard ratio, with 12 months accrual
and 12 months follow-up. This will require a total of
516 patients to be randomized 1:1, allowing for a 5% loss
to follow-up.
Secondary outcome
The rate of decline in renal clearance is reported by
most studies as a monthly decline of 0.3 ml/min/
1.73 m2/month (reported range 0.3–0.4) [26–30]. At the
same significance level, this sample size would provide
just under 95% power to detect a difference in rate of
0.05 ml/min/1.73 m2/month, assuming linear change
assessments at 0,1,2,3,5,7,9,11 and 13 months, and a
(conservative) autocorrelation of 0.30.
Recruitment
Participants will be recruited over a 12-month period at
30 centre-based haemodialysis centres throughout the
UK, including satellite units affiliated with main centres.
All adult patients new to centre-based HD treatment will
be screened using the trial eligibility criteria. Patients who
start dialysis in a planned fashion will be approached in
chronic kidney disease clinics at the point of deciding a
convenient start date. Patients starting treatment that is
unplanned will be approached at the point it is decided
they will require long-term dialysis.
Allocation
Both planned and unplanned incident HD patients will
be randomized after informed consent has been obtained
and at the point of commencing haemodialysis as an
outpatient. Randomization will be 1:1 to the BI interven-
tion and control groups, with random permuted blocks,
stratified by centre (main or satellite where dialysis will
commence.
Fig. 1 Schema for BISTRO Trial
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Randomization will be during office hours using a secure
centralized web-based, automated computer-generated
randomization system provided by the Keele University
Clinical Trials Unit (CTU). Authorized personnel at the
trial site will be allocated personalized log-in details by
Keele CTU to access this system. In the event the centre
network is not functioning they will call the Keele CTU
and authorized staff will perform the randomization on
the centre’s behalf.
Blinding
BI readings will be taken in both study groups but the
results concealed from the clinical teams and patients in
the controls. To ensure blinding to BI data in control
subjects and to minimize performance bias, BI measure-
ments will be taken independently from clinical fluid as-
sessments by the research nurse. The full BI dataset will
be stored for all patients using the proprietary software,
but in the BI intervention arm the key BI metrics used
for informing the clinical decision will be transferred to
the clinical assessment CRF (BISTRO study intervention
record) prior to their use.
Data collection: methods and management
Demographic data, clinical and bioimpedance assessments
of fluid status
Data at baseline and subsequently (see Table 1) will be
collected on paper CRFs at the specified time intervals –
with the option of recording additional fluid assessment
if clinically indicated (e.g. following hospital admission).
Fluid assessments are recorded on the BISTRO study
intervention record, onto which the BI-determined
normally hydrated weight is transferred in the interven-
tion group only (see Fig. 2). Electronic capture of a full
bioimpedance dataset is supported by the device soft-
ware and stored on the dialysis unit server for later
transfer to the CTU.
Residual kidney function
This is determined from a urine collection and routinely
collected blood samples for urea and creatinine. The re-
search nurse will enter these data into a GFR calculator
to calculate residual kidney function. The whole proced-
ure will be carried out in accordance with a study-
specific standard operating procedure for measurement
of residual renal function in haemodialysis patients by
the Leeds Teaching Hospitals NHS Trust and adapted
for the BISTRO trial.
Patient reported outcomes
These will be administered using a patient booklet
containing the items listed in Table 1. The Montreal
Cognitive Assessment (MoCA) will be administered by
research nurses who have received training.
Unit-level survey of practice patterns
A unit-level survey will be completed annually for the
project duration by the Lead Consultant for each dialysis
Unit (see Table 2 for items).
Routine clinical data collected by the UK Renal Registry
Routine clinical data collected by units for the Renal Regis-
try returns will be transferred to the CTU for incorporation
into the trial database annually (2017, 2018 and final down-
load at study end) in the form of an electronic download
(following appropriate testing procedures to ensure data in-
tegrity). This includes data collected for individual dialysis
sessions (e.g. pre- and post-dialysis weights and blood pres-
sures, dialysis prescription), haematology and biochemistry
results, and treatment modality timelines, using the Renal
Registry Dataset V4.2 (www.renalreg.org). If sites are not
providing this information as part of their routine submis-
sion to the UKRR then they will be required to send a
separate file with the fields by an appropriate secure mech-
anism to the UKRR at least once at the end of the trial.
Admission and discharge dates, diagnostic and procedural
codes will be obtained from Hospital Episodes and Statistics
(or its equivalent body) by data linkage. If subjects choose
to drop out of the study they will asked if they are still will-
ing for their routine data be used (this is consented for
independently).
Statistical methods
Analysis will be in accordance with a predetermined
statistical analysis plan and will be conducted blind to
treatment allocation. Statistical significance will be set as
p ≤ .05 (two-tailed).
Primary outcome
Time to anuria will be analysed on an intention-to-treat
basis (as the primary analysis) and on an as-treated basis
(as the secondary analysis) using competing risks survival
analysis [32], to estimate the relative risk (as expressed by
the sub-hazard ratio) of the outcome (anuria) in patients
where BI is used compared to control patients, accounting
for the competing risks (death, transplantation). Patients
undergoing modality change or recovery will be censored
at the point of treatment switch. The analysis will control
for known baseline covariates affecting residual function
[26, 29], i.e. age, race, sex, comorbidities (separately or using
a validated scoring system), antihypertensive drug use (ACE
inhibitors/ARBs, calcium antagonists) and diuretic use.
Secondary outcomes
Difference in rate of decline in renal clearance will be ana-
lysed using a random slopes linear mixed model, with ad-
justment for baseline characteristics, as for the primary
outcome. We will analyse the effect of randomization on
fluid status and body composition as determined by BI (to
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ascertain the effect of the intervention on the fluid assess-
ment decision) and undertake corresponding appropriate
analyses of the other secondary outcomes such as (i) dia-
lysis-related symptoms and treatment efficacy (e.g. inter-
dialytic fluid gain, falls, post-dialysis recovery time), (ii)
critical events such as cardiovascular events and interven-
tions, access-related interventions/failures and death, and
(iii) patient-reported measures (e.g. EQ-5D-5 L, SF-12,
PAM, POS-S renal, CSRI CKD). In analysing the effect of
the intervention on patient activation measures we will
look to see if this is associated with objective measures of
fluid management, e.g. inter-dialytic fluid gain which, fol-
lowing adjustment for comorbidity, is a surrogate measure
of patient survival.
Subgroup analyses
Pre-specified subgroup analyses will be limited to comor-
bid conditions that affect management of fluid status –
Fig. 2 BISTRO fluid assessment record. At each fluid assessment the clinician will complete this chart, recording any target weight adjustment,
planned interventions to achieve this and any factors that have influenced their decision to set or override the suggested target weight. Only in the
those patients randomised to the intervention will the normally hydrated weight post dialysis be completed and thus available to the clinician
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specifically heart failure and diabetic status – and will be
assessed through an interaction term in the model [33].
They will also explore, in a separate analysis, the effects of
unit-level practice patterns (Table 2) as defined by
our pre-study survey of 66 dialysis units, e.g. routine
use of blood volume monitors, BI, dialysate sodium
concentration, including stated approaches to fluid man-
agement (e.g. intention to reduce weight to avoid the use of
antihypertensive drugs).
Economic evaluation
Economic analysis will be carried out to explore the rela-
tive cost-effectiveness of the intervention compared to
standard management. The base-case analysis will adopt
an NHS and personal social services perspective [34].
Additional analyses will be undertaken from a wider soci-
etal perspective, by considering private (patient-incurred)
costs and productivity loss, using added questions from a
modified Client Services Receipt Inventory developed for
patients with chronic kidney disease. Costs and benefits
accruing in the future will be discounted to reflect positive
time preference.
A trial-based analysis will be carried out alongside the
BISTRO study to determining the cost-effectiveness of
the compared strategies on the basis of patient-level data
obtained within the study period. Results will be pre-
sented in the form of incremental cost-effectiveness
ratios, reflecting the extra cost for an additional unit of
outcome. The main outcome will be the QALY, deter-
mined from participants’ responses to the EuroQol EQ-
5D-5 L [21] and SF-12 [35] instruments at baseline and
3-monthly thereafter. To account for uncertainty, the in-
herent uncertainty due to sampling variation, the joint
distribution of differences in cost and outcomes (QALYs)
will be derived by carrying out a large number of non-
parametric bootstrap simulations [36]. Results will be
depicted on a cost-effectiveness plane and will be plotted
as cost-effectiveness acceptability curves (CEACs) [37].
CEACs will show the probability of the BI-guided and
standard fluid management options being cost-effective
across a range of possible values of willingness to pay for
an additional QALY. Additional work will involve build-
ing a decision analytic model to assess costs and effects
likely to accrue beyond the study follow-up period.
Monitoring
The Keele CTU data management team will perform data
quality checks of CRF data. Data queries will be entered to
a log that will be sent to the trial manager, who will work
with each site to resolve data queries in a timely fashion
and provide further training as required. This, along with
safety reports, will inform a risk-based approach towards
assessing a need for any onsite monitoring visits. Trial
monitoring reports will be reviewed by the Trial Manage-
ment Group, Data Management Committee (DMC) and
Trial Steering Committee (TSC). These committees are
constituted according to NIHR Health Technology and
Assessment Board guidelines and are fully (DMC) or >75%
independent (TMC). The DMC will receive un-blinded
Table 2 Unit level practice patterns, measured annually: first
completion just before the first patient is enrolled
Dialysate sodium concentration
• Is there a standard sodium concentration in your unit?
• What is the concentration of sodium used most frequently?
• What proportion of patients have an individualised sodium
concentration?
• If individual sodium used
o If low, what reason? If high, what reason?
o Is your practice to match the plasma sodium?
Nutrition and sodium intake
• Does your HD unit have a dedicated dietitian? If so, how much time
per patient do they have?
• Do you have a policy on sodium restriction? If so what is the
advised intake?
• Do you have a policy on fluid restriction? If so what is the advised
intake?
• What information/training is given to nurses on the HD unit about
fluid/salt restrictions?
• Are patients given written advice about dietary intake and
restrictions?
Diuretics
• Are the majority patients with residual kidney function routinely
prescribed loop diuretics?
• What is the typical dose (e.g. Furosemide, Bumetanide)?
• Do you routinely use other diuretics (metolazone, thiazides,
aldosterone inhibitors)?
Incremental dialysis
• Is it routine practice in your unit to commence HD incrementally?
• If so, is this to preserve residual kidney function?
• What proportion of patients on your unit do (a) 1 or (b) 2 sessions
per week in the context of incremental start?
Measurement of residual Kidney Function
• Do you routinely measure residual kidney function on your unit? If
so how frequently?
• If so, do you use this to reduce the (a) frequency, (b) length of
dialysis sessions?
Assessment and prescription
• Do you have a standardised protocol for assessing fluid status in
new HD patients?
• Protocol or not, in addition to clinical assessment do you routinely
use (a) bioimpedance – of so state device, (b) Chest Xray,(c)
Echocardiogram (d) central vein diameter, (e) blood volume
monitoring?
• Who assesses fluid status on your unit (a) consultants (b) HD
dedicated staff grades (c) HD nurses (d) training grade doctors.
Fluid management strategies
• Who prescribes fluid management on your unit (a) consultants (b)
HD dedicated staff grades (c) HD nurses (d) training grade doctors.
• Do you have a policy to maximise UF rates in your unit? If so, what
is the maximum rate permitted?
• If you are changing the target weight, typically what is the maximum
change per session you would prescribe? (Exclude urgent situations
and tell us if there is no specific policy on this).
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safety data at the group level and the TMC will receive re-
ports from the DMC.
Discussion
Adoption of new technologies to support clinical manage-
ment requires scrutiny no less than the introduction of
new pharmacological interventions. Bioimpedance is not
new, although the technology has become more sophisti-
cated, and the actual process of taking measurements is
both safe and reproducible in trained hands [12]. Intro-
duction of this technology to the clinical setting has been
found to be acceptable to patients and many dialysis units
around the world are now undertaking regular measure-
ments as part of clinical practice. The evidence that BI
gives clinicians new information about their patients’ body
composition is strong and it is increasingly clear that the
combination of reduced lean tissue mass and excess extra-
cellular water (ECW) in proportion to intracellular water
(ICW) – however this is expressed (phase angle, ECW/
ICW, overhydration index) –, is associated with worse
clinical outcomes.
The question remains how to use this additional infor-
mation in day-to-day clinical management. Should clini-
cians attempt to normalize measured ECW to the patient’s
normally hydrated weight or should they deliberately
volume-deplete patients by the end of their dialysis treat-
ment in an attempt to control blood pressure and undo
the damage associated with long-standing hypertension?
Without an independent measure of body composition,
how do clinicians know which of these strategies they
are employing? Given the potential to cause harm by
excessively and serially volume-depleting patients, it
would seem crucial that this practice is properly eval-
uated in a clinical trial. BISTRO is designed to fill
this knowledge gap, focussing on the simplest of po-
tential casualties of volume depletion, residual kidney
function, a commodity that has been shown to be of
consistent benefit to dialysis patients.
Trials assessing fluid management are challenging to
undertake. One of the reasons for this is that assessing
fluid status and implementing change are an example of
complex decision making. The clinician, working with the
patient, needs to take several things into account (e.g.
symptoms, dietary intake, multiple comorbidities, dialysis
tolerance, conflicting diagnostic information) and choose
from several interventions (e.g. salt restriction, increased
or reduced fluid removal, pharmacological interventions,
and often more than one). One of the lessons learned
from the UK-Shanghai BI trial in peritoneal dialysis pa-
tients [17], which attempted to collect decisions made at
the time of fluid status assessment, was just this –these
decisions are complex, multiple and bi-directional over
time. To try and understand this better for BISTRO we
have developed a template that will both help clinicians
order their approach to fluid assessment and clarify why
they chose to over-ride the BI-derived normally hydrated
weight. The disadvantage of this approach may be that
fluid management is ‘improved’ in the control group, so
putting the intervention under greater pressure to demon-
strate a benefit; the advantage is a better understanding
of the intervention and even if the study is negative
we will have, for the first time, a validated template
to support fluid management.
Performance bias is also a risk in this type of study, which
has inevitably to be an open-label design. We have endea-
voured to minimize this risk by separating the BI measure-
ments from the clinical assessments and blinding both
clinicians and participants to the BI measures in the control
group. This will be a major focus of the training sessions
that will be undertaken at all the sites, which will also en-
sure consistency in how the intervention is implemented.
Finally, in designing the trial we carefully considered the
pros and cons of a cluster (dialysis unit) versus a patient-
level randomisation. Apart from practical reasons (for ex-
ample patients often transfer from the main dialysis unit to
a satellite centre after initiation of treatment, potentially for-
cing either drop in or out of the intervention) we became
aware of significant variation between sites in their approach
to fluid management. We undertook a survey of UK dialysis
units to establish this, confirming that the number of sites
required to get a balanced cluster randomization would have
been impractical [11]. We have, however, used the informa-
tion from this survey to undertake an annual survey of prac-
tice patterns during the conduct of the trial to allow us to
correct for these in the primary and secondary analyses. Un-
derstanding the interactions between these practice patterns
and clinical outcomes are an additional, potentially useful
benefit of the study.
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